PD-L1 expression and tumor mutational burden were not associated with survival.
Enrollment declined 43% from 2019 to 2020.
Factors associated with poor survival were advanced age and male sex.
The 12-month progression-free survival rate was superior in the lurbinectedin arm.
The combinations conferred benefits in nonsquamous non-small cell lung cancer only.
The time from cytohistological diagnosis to treatment initiation was longer in 2019 than in 2020.
Researchers are evaluating whether specific anticancer therapies affect antibody levels.
Perioperative COVID-19 was associated with a 30-day mortality rate of 26%.